Mammography World Markets
Figure 6.23: Participation in Breast Cancer Screening by Age in Japan, 2007 108
Figure 6.24: Participation in BreastScreen Australia by Women Aged 50-69, 2000-2010 110
Figure 6.25: MBS-Funded Mammography Services by Age Group in Australian Women, 2011 111
Figure 7.1: Global Market for Mammography Systems, 2011-2018 113
Figure 7.2: Global Market for FFDM Mammography Equipment, 2011-2018 114 Figure 7.3: Global Market Leaders in Mammography Equipment Market, 2011 115 Figure 7.4: U.S. Market for Full-Field Digital Mammography Market, 2011-2018 116 Figure 7.5: U.S. Mammography Units and Facilities, 2000-2011 117 Figure 7.6: Growth in Number of FFDM Units and Facilities in the U.S., 2004-2010 118 Figure 7.7: Rest of the World Market for Mammography Equipment, 2011-2018 119 Figure 7.8: European Market for Mammography System, 2011-2018 120 Figure A2.1: Tumor Sizes 140 Figure A5.1: Improvement in Cancer Detection 154 Figure A5.2: Increased Breast Cancer Detection Using Tomosynthesis 155 Figure A5.3: Reduced Recall Rates 155 Figure A5.4: Added Value for Calcifications 156 Figure A5.5: Value of Tomosynthesis in Fatty Breasts 157 Figure A5.6: Greater Perception of Extent of Disease Using Tomosynthesis 158 Figure A5.7: Two-View Tomosynthesis Optimizes Chance for Cancer Detection 158 Figure A5.8: Dose Levels of 2D and Tomo Exams Compared to Natural Background Radiation 159 Figure A6.1: Breast Cancer in the U.S. by Race and Stage at Diagnosis 162 Figure A6.2: Female Breast Cancer Treatment Patterns by Stage 163 Figure A6.3: Five-Year Survival Rates for Breast Cancer Patients by Race and Stage at Diagnosis 164 Figure A6.4: Distribution of Colon and Rectum Cancer by Race and Stage at Diagnosis 167 Figure A6.5: Colon Cancer Treatment Patterns by Stage 167 Figure A6.6: Rectal Cancer Treatment Patterns by Stage 168 Figure A6.7: Five-Year Survival Rates for Colon and Rectal Cancer Patients by Race and Stage at Diagnosis 169 Figure A6.8: Distribution (%) of Non-Hodgkin Lymphoma Patients by Race and Stage at Diagnosis 170Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
